Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from ...

Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

For Immediate Release Chicago, IL – July 10, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog.

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is using “deceptive marketing” to sell copycat versions of its obesity ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

The lack of details about which countries are involved and which companies will be impacted as a result of the new trade deal ...

New data from Novo Nordisk and Eli Lilly indicate their weight-loss drugs show promising results with mild side effects. Novo Nordisk's CagriSema reported significant weight loss and positive outcomes ...

Novo Nordisk presented trial results from its trials evaluating the efficacy of CagriSema, another weight-loss drug. Patients with chronic obesity lost an average of 22.7% of their body mass at 68 ...